Pernix Therapeutics, LLC
) has recently entered into a co-promotion agreement with
Cumberland Pharmaceuticals Inc
) for its gastroenterology drug, Omeclamox-Pak.
As per the terms of the agreement, Cumberland will promote the
drug to gastroenterologists across the U.S. through its field
sales force while Pernix will promote the product through its
specialty sales force focusing on select primary care
We note that Omeclamox-Pak is indicated for the treatment of
Helicobacter pylori (H. pylori) infection and duodenal ulcer
disease. The drug was approved in the U.S. in 2011.
We remind investors that Pernix Therapeutics entered into a
license and supply agreement with a privately-held company
Gastro-Entero Logic for the rights of Omeclamox-Pak in
Pernix promotes its branded products in two main segments -
pediatric and gastroenterology products. Apart from
Omeclamox-Pak, Pernix also has another drug, Rezyst, in its
portfolio in the gastroenterology market. Rezyst is a probiotic
blend to promote dietary management.
In recent times, Pernix has been strengthening its product
portfolio through acquisitions and promotion agreements.
Pernix completed the acquisitions of Cypress Pharma (a
privately-owned generic pharmaceutical company) and Hawthorn
Pharma (a privately-owned branded pharmaceutical company) at the
end of Dec 2012.
In early Mar 2013, Pernix completed the acquisition of Somaxon
Pharmaceuticals, thereby adding insomnia drug Silenor to its
Meanwhile, Pernix completed the sale of some of its non-core
assets to privately-held Breckenridge Pharmaceutical in Sep
We are encouraged by Pernix's efforts to consolidate its
Pernix currently carries a Zacks Rank #3 (Hold). Right now,
) look attractive with a Zacks Rank #2 (Buy).
ACTAVIS PLC (ACT): Free Stock Analysis Report
AKORN INC (AKRX): Free Stock Analysis Report
CUMBERLAND PHAR (CPIX): Free Stock Analysis
PERNIX THERAPTC (PTX): Free Stock Analysis
To read this article on Zacks.com click here.